Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.177.17. Please contact the publisher to request reinstatement.
1.
Salomon  JSzepietowski  JCProniewicz  A Psoriatic nails: a prospective clinical study.  J Cutan Med Surg 2003;7 (4) 317- 321PubMedGoogle ScholarCrossref
2.
Jiaravuthisan  MMSasseville  DVender  RBMurphy  FMuhn  CY Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.  J Am Acad Dermatol 2007;57 (1) 1- 27PubMedGoogle ScholarCrossref
3.
de Jong  EMSeegers  BAGulinck  MKBoezeman  JBvan De Kerkhof  PC Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients.  Dermatology 1996;193 (4) 300- 303PubMedGoogle ScholarCrossref
4.
Tosti  APiraccini  B Dermatological diseases  In: Scher  RK,  Daniel CR,Tosti  A,Elewski  B, Fleckman  P,Rich  P, eds.  Nails: Diagnosis, Therapy, Surgery. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2005Google Scholar
5.
Grover  CReddy  BSUma Chaturvedi  K Diagnosis of nail psoriasis: importance of biopsy and histopathology.  Br J Dermatol 2005;153 (6) 1153- 1158PubMedGoogle ScholarCrossref
6.
Zaias  N Psoriasis of the nail. A clinical-pathologic study.  Arch Dermatol 1969;99 (5) 567- 579PubMedGoogle ScholarCrossref
7.
Rich  PScher  RK Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.  J Am Acad Dermatol 2003;49 (2) 206- 212PubMedGoogle ScholarCrossref
8.
Parrish  CASobera  JOElewski  BE Modification of the Nail Psoriasis Severity Index.  J Am Acad Dermatol 2005;53 (4) 745- 746PubMedGoogle ScholarCrossref
9.
Mahrle  GSchulze  HJFärber  LWeidinger  GSteigleder  GK Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.  J Am Acad Dermatol 1995;32 (1) 78- 88PubMedGoogle ScholarCrossref
10.
Brazzelli  VMartinoli  SPrestinari  FBorroni  G An impressive therapeutic result of nail psoriasis to acitretin.  J Eur Acad Dermatol Venereol 2004;18 (2) 229- 230PubMedGoogle ScholarCrossref
11.
Rabinovitz  HSScher  RKShupack  JL Response of psoriatic nails to the aromatic retinoid etretinate.  Arch Dermatol 1983;119 (8) 627- 628PubMedGoogle ScholarCrossref
12.
Baran  R Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects.  Clin Exp Dermatol 1986;11 (2) 148- 152PubMedGoogle ScholarCrossref
13.
Cassell  SEBieber  JDRich  P  et al.  The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis.  J Rheumatol 2007;34 (1) 123- 129PubMedGoogle Scholar
14.
Van den Bosch  FReece  RBeherens  F  et al Clinically important nail psoriasis improvements are achieved with adalibumab (HUMIRA): results from a large open-prospective study (STEREO).  European League Against Rheumatism Annual Scientific Meeting, 2007 poster presentation; June 13-16, 2007; Barcelona, Spain
15.
Bianchi  LBergamin  Ade Felice  CCapriotti  EChimenti  S Remission and time of resolution of nail psoriasis during infliximab therapy.  J Am Acad Dermatol 2005;52 (4) 736- 737PubMedGoogle ScholarCrossref
16.
Rich  PGriffiths  CEReich  K  et al.  Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.  J Am Acad Dermatol 2008;58 (2) 224- 231PubMedGoogle ScholarCrossref
17.
Körver  JELangewouters  AMVan De Kerkhof  PCPasch  MC Therapeutic effects of a 12-week course of alefacept on nail psoriasis.  J Eur Acad Dermatol Venereol 2006;20 (10) 1252- 1255PubMedGoogle ScholarCrossref
18.
Lawry  M Biological therapy and nail psoriasis.  Dermatol Ther 2007;20 (1) 60- 67PubMedGoogle ScholarCrossref
Study
March 2009

Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis

Author Affiliations

Author Affiliations: Departments of Dermatology, University of Bologna, Bologna Italy (Drs Tosti and Piraccini), Miller School of Medicine, University of Miami, Miami, Florida (Drs Ricotti and Romanelli), and Istituto Fisioterapici Ospitalieri, Rome, Italy (Dr Cameli).

Arch Dermatol. 2009;145(3):269-271. doi:10.1001/archdermatol.2008.600
Abstract

Objective  To evaluate the therapeutic efficacy of acitretin in patients with isolated nail psoriasis.

Design  Open study involving 36 patients with moderate to severe nail psoriasis treated with acitretin.

Setting  University-based outpatient dermatology clinic specializing in nail diseases.

Patients  A total of 27 men and 9 women (mean age, 41 years) with nail psoriasis.

Intervention  Therapy consisted of acitretin, 0.2 to 0.3 mg/kg/d, for 6 months.

Main Outcome Measures  Clinical evaluation, and Nail Psoriasis Severity Index (NAPSI) and modified NAPSI scores before therapy, every 2 months during therapy, and 6 months after treatment.

Results  The mean percentage of reduction of the NAPSI score after treatment was 41%; the mean percentage of reduction of the modified NAPSI score of the target nail was 50%. Clinical evaluation at 6 months showed complete or almost complete clearing of the nail lesions in 9 patients (25%), moderate improvement in 9 (25%), mild improvement in 12 (33%), and no improvement in 6 (11%).

Conclusion  Results from low-dose acitretin therapy show NAPSI score reductions comparable with those studies evaluating biologic drugs for nail psoriasis and suggest that low-dose systemic acitretin should be considered in the treatment of nail psoriasis.

×